These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26428385)

  • 1. The Development of Prophylactic and Therapeutic EBV Vaccines.
    Smith C; Khanna R
    Curr Top Microbiol Immunol; 2015; 391():455-73. PubMed ID: 26428385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine Development for Epstein-Barr Virus.
    Cohen JI
    Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
    Cui X; Snapper CM
    Front Immunol; 2021; 12():734471. PubMed ID: 34691042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature.
    Winter JR; Jackson C; Lewis JE; Taylor GS; Thomas OG; Stagg HR
    J Glob Health; 2020 Jun; 10(1):010404. PubMed ID: 32257152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice.
    Zhang X; Chen Y; Wang S; Zhong L; Xiang Z; Zhang X; Zhang S; Zhou X; Zhang W; Zhou Y; Zhang Q; Liang J; Luo Y; Wang Y; Chen L; Ye X; Feng Q; Zeng MS; Liu Y; Zeng YX; Shao Y; Xu M
    Emerg Microbes Infect; 2024 Dec; 13(1):2412640. PubMed ID: 39387189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.
    Dasari V; Bhatt KH; Smith C; Khanna R
    Expert Rev Vaccines; 2017 Apr; 16(4):377-390. PubMed ID: 28276306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of currently unavailable herpes virus vaccines.
    Rajčáni J; Bánáti F; Szenthe K; Szathmary S
    Expert Rev Vaccines; 2018 Mar; 17(3):239-248. PubMed ID: 29313728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination against the Epstein-Barr virus.
    Rühl J; Leung CS; Münz C
    Cell Mol Life Sci; 2020 Nov; 77(21):4315-4324. PubMed ID: 32367191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development.
    Dasari V; Sinha D; Neller MA; Smith C; Khanna R
    Expert Rev Vaccines; 2019 May; 18(5):457-474. PubMed ID: 30987475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.
    Leskowitz R; Fogg MH; Zhou XY; Kaur A; Silveira EL; Villinger F; Lieberman PM; Wang F; Ertl HC
    J Virol; 2014 May; 88(9):4721-35. PubMed ID: 24522914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.
    Sun C; Chen XC; Kang YF; Zeng MS
    Front Immunol; 2021; 12():677027. PubMed ID: 34168649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice.
    van Zyl DG; Tsai MH; Shumilov A; Schneidt V; Poirey R; Schlehe B; Fluhr H; Mautner J; Delecluse HJ
    PLoS Pathog; 2018 Dec; 14(12):e1007464. PubMed ID: 30521644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response of mice to a latency membrane protein 2 multiepitope antigen of Epstein-Barr virus applied as DNA vaccine and/or peptide vaccine.
    Li W; Chen Q; Chen H; Rao P; Xue X; Chen S; Zhu S; Zhang L
    Acta Virol; 2013; 57(1):51-8. PubMed ID: 23530824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation.
    Khanna R; Moss DJ; Burrows SR
    Immunol Rev; 1999 Aug; 170():49-64. PubMed ID: 10566141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Evasion by Epstein-Barr Virus.
    Ressing ME; van Gent M; Gram AM; Hooykaas MJ; Piersma SJ; Wiertz EJ
    Curr Top Microbiol Immunol; 2015; 391():355-81. PubMed ID: 26428381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection.
    Pender MP
    Autoimmun Rev; 2009 Jun; 8(7):563-8. PubMed ID: 19254880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic CD4+ T-cells specific for EBV capsid antigen BORF1 are maintained in long-term latently infected healthy donors.
    Dowell AC; Haigh TA; Ryan GB; Turner JE; Long HM; Taylor GS
    PLoS Pathog; 2021 Dec; 17(12):e1010137. PubMed ID: 34882759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress, prospects, and problems in Epstein-Barr virus vaccine development.
    Balfour HH
    Curr Opin Virol; 2014 Jun; 6():1-5. PubMed ID: 24632197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virology. Epstein-Barr virus turns 50.
    Lieberman PM
    Science; 2014 Mar; 343(6177):1323-5. PubMed ID: 24653027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.